These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

971 related items for PubMed ID: 22068628

  • 1. An overview of letrozole in postmenopausal women with hormone-responsive breast cancer.
    Barnadas A, Estévez LG, Lluch-Hernández A, Rodriguez-Lescure A, Rodriguez-Sanchez C, Sanchez-Rovira P.
    Adv Ther; 2011 Dec; 28(12):1045-58. PubMed ID: 22068628
    [Abstract] [Full Text] [Related]

  • 2. Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
    Wardley AM.
    Adv Ther; 2008 Dec; 25(12):1257-75. PubMed ID: 19096768
    [Abstract] [Full Text] [Related]

  • 3. Review of the development of letrozole and its use in advanced breast cancer and in the neoadjuvant setting.
    Bhatnagar AS.
    Breast; 2006 Feb; 15 Suppl 1():S3-13. PubMed ID: 16500235
    [Abstract] [Full Text] [Related]

  • 4. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J.
    Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
    [Abstract] [Full Text] [Related]

  • 5. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S, Pippen J, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, Press MF, Maltzman J, Florance A, O'Rourke L, Oliva C, Stein S, Pegram M.
    J Clin Oncol; 2009 Nov 20; 27(33):5538-46. PubMed ID: 19786658
    [Abstract] [Full Text] [Related]

  • 6. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
    Breast International Group (BIG) 1-98 Collaborative GroupSenology Center of Eastern Switzerland, Kantonsspital, St. Gallen, and the Swiss Group for Clinical Cancer Research, Switzerland., Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A.
    N Engl J Med; 2005 Dec 29; 353(26):2747-57. PubMed ID: 16382061
    [Abstract] [Full Text] [Related]

  • 7. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
    Monnier AM.
    Expert Rev Anticancer Ther; 2007 May 29; 7(5):627-34. PubMed ID: 17492927
    [Abstract] [Full Text] [Related]

  • 8. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
    Gradishar WJ.
    Oncology; 2005 May 29; 69(1):1-9. PubMed ID: 16088229
    [Abstract] [Full Text] [Related]

  • 9. Update of the BIG 1-98 Trial: where do we stand?
    Joerger M, Thürlimann B.
    Breast; 2009 Oct 29; 18 Suppl 3():S78-82. PubMed ID: 19914548
    [Abstract] [Full Text] [Related]

  • 10. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
    Rasmussen BB, Regan MM, Lykkesfeldt AE, Dell'Orto P, Del Curto B, Henriksen KL, Mastropasqua MG, Price KN, Méry E, Lacroix-Triki M, Braye S, Altermatt HJ, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Gusterson BA, Thürlimann B, Coates AS, Viale G, BIG 1-98 Collaborative and International Breast Cancer Study Groups.
    Lancet Oncol; 2008 Jan 29; 9(1):23-8. PubMed ID: 18083065
    [Abstract] [Full Text] [Related]

  • 11. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A.
    J Clin Oncol; 2007 Feb 10; 25(5):486-92. PubMed ID: 17200148
    [Abstract] [Full Text] [Related]

  • 12. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
    Cohen MH, Johnson JR, Li N, Chen G, Pazdur R.
    Clin Cancer Res; 2002 Mar 10; 8(3):665-9. PubMed ID: 11895893
    [Abstract] [Full Text] [Related]

  • 13. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
    Carpenter R.
    Eur J Surg Oncol; 2008 Jul 10; 34(7):746-55. PubMed ID: 18296017
    [Abstract] [Full Text] [Related]

  • 14. Role of anastrozole across the breast cancer continuum: from advanced to early disease and prevention.
    Nabholtz JM.
    Oncology; 2006 Jul 10; 70(1):1-12. PubMed ID: 16439860
    [Abstract] [Full Text] [Related]

  • 15. Letrozole as adjuvant endocrine therapy in postmenopausal women with breast cancer.
    Koeberle D, Thuerlimann B.
    Expert Rev Anticancer Ther; 2006 Jan 10; 6(1):5-10. PubMed ID: 16375638
    [Abstract] [Full Text] [Related]

  • 16. Are aromatase inhibitors superior to antiestrogens?
    Howell A, Buzdar A.
    J Steroid Biochem Mol Biol; 2005 Feb 10; 93(2-5):237-47. PubMed ID: 15860266
    [Abstract] [Full Text] [Related]

  • 17. Are all aromatase inhibitors the same? A review of the current evidence.
    Jänicke F.
    Breast; 2004 Dec 10; 13 Suppl 1():S10-8. PubMed ID: 15585378
    [Abstract] [Full Text] [Related]

  • 18. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer.
    Dowsett M, Pfister C, Johnston SR, Miles DW, Houston SJ, Verbeek JA, Gundacker H, Sioufi A, Smith IE.
    Clin Cancer Res; 1999 Sep 10; 5(9):2338-43. PubMed ID: 10499602
    [Abstract] [Full Text] [Related]

  • 19. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
    Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T, ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group.
    Cancer; 2003 Nov 01; 98(9):1802-10. PubMed ID: 14584060
    [Abstract] [Full Text] [Related]

  • 20. A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer.
    McCaig FM, Renshaw L, Williams L, Young O, Murray J, Macaskill EJ, McHugh M, Hannon R, Dixon JM.
    Breast Cancer Res Treat; 2010 Feb 01; 119(3):643-51. PubMed ID: 19941160
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.